ESR1 and breast carcinoma: Interestingly, increased HDAC1 activity due to its phosphorylation by S6K1 at the downstream of mTORC1 signaling pathway has been shown to inhibit estrogen receptor-alpha expression; thus leading to therapy resistance in breast cancer (54).